GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Status:
Completed
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability, feasibility and
biological activity (immunogenicity) of the actively personalized vaccination (APVAC) concept
in newly diagnosed glioblastoma (GB) patients.
Phase:
Phase 1
Details
Lead Sponsor:
immatics Biotechnologies GmbH
Collaborators:
BCN Peptides Biontech AG BioNTech SE EU-funded GAPVAC Consortium University Hospital Tuebingen